Search

Your search keyword '"Carlos Augusto Pérez Niño"' showing total 3 results
Start Over Author "Carlos Augusto Pérez Niño"
3 results on '"Carlos Augusto Pérez Niño"'

1. Second Colombian Consensus on the Management of Post-menopausal Osteoporosis: 2017 update

Author

Adriana Medina Orjuela, Óscar Rosero Olarte, Pedro Nel Rueda Plata, Fabio Sánchez Escobar, Monique Chalem Choueka, Miguel Ángel González Reyes, Alejandro Román González, Alexandra Terront Lozano, Amanda Páez Talero, Camilo Rueda Belt, Carlos Alfonso Builes Barrera, Carlos Augusto Pérez Niño, Daniel G. Fernández Ávila, David Vásquez Awad, Deyanira González Devia, Edgar Pinilla Pabón, Eduardo Antonio Reina Valdivieso, Esdras Martín Vásquez Mejía, Francisco Iván Vargas Grajales, Francisco Linares Restrepo, Geraldine Altamar Canales, Gustavo Adolfo Molina Uribe, Gustavo Adolfo Pineda Acero, Henry Mauricio Arenas Quintero, Jorge Augusto Vélez Patiño, José Fernando Molina Restrepo, Juan José Jaller Raad, Ricardo Londoño Gutiérrez, Patricia Clark, Orlando Angulo Ceballos, and Carlos Federico Molina Castaño

Subjects
medicine.medical_specialty, Population ageing, business.industry, Osteoporosis, 030209 endocrinology & metabolism, General Medicine, Disease, Scientific literature, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Denosumab, Family medicine, Post menopausal osteoporosis, Epidemiology, medicine, 030212 general & internal medicine, business, Working group, medicine.drug
Abstract

The Colombian Osteoporosis and Mineral Metabolism Association met in early 2017 to update the Colombian Consensus on Osteoporosis. This was first issued in 2005, and is seen as a necessary step in view of the underdiagnosed status of this disease, and the expected impact of population aging. A technical team was formed with specialists with long experience across multiple disciplines, who were assigned to four working groups: definitions and epidemiology, diagnosis, pharmacological treatment, and non-pharmacological treatment. After a scientific literature review and a series of meetings, the definitions and recommendations are summarized in this article.

Published
2018

2. Second Colombian Consensus on the Management of Post-menopausal Osteoporosis: 2017 Update

Author

Alexandra Terront Lozano, Francisco Vargas Grajales, José Fernando Molina Restrepo, Óscar Rosero Olarte, Fabio Sánchez Escobar, Geraldine Altamar Canales, Eduardo Antonio Reina Valdivieso, Juan José Jaller Raad, Adriana Medina Orjuela, Alejandro Román González, Francisco Linares Restrepo, Ricardo Londoño Gutiérrez, Monique Chalem Choueka, Gustavo Adolfo Molina Uribe, Edgar Pinilla Pabón, Deyanira González Devia, David Vásquez Awad, Gustavo Adolfo Pineda Acero, Carlos Augusto Pérez Niño, Pedro Nel Rueda Plata, Henry Mauricio Arenas Quintero, Esdras Martín Vásquez Mejía, Jorge Augusto Vélez Patiño, Miguel Ángel González Reyes, Camilo Rueda Beltz, Carlos Alfonso Builes Barrera, Amanda Páez Talero, and Daniel G. Fernández Ávila

Subjects
Gynecology, medicine.medical_specialty, Oestrogen replacement therapy, Bisfosfonatos, business.industry, Enfermedades óseas metabólicas, 030209 endocrinology & metabolism, Osteoporosis posmenopáusica, Densidad ósea, Guía de práctica clínica, 03 medical and health sciences, Teriparatida, 0302 clinical medicine, Rheumatology, Preparaciones farmacéuticas, Post menopausal osteoporosis, Medicine, Terapia de reemplazo de estrógeno, 030212 general & internal medicine, Denosumab, business, Fracturas osteoporóticas
Abstract

Resumen La Asociación Colombiana de Osteoporosis y Metabolismo Mineral se reunió a principios de 2017 para actualizar el Consenso Colombiano de Osteoporosis, elaborado por primera vez en 2005, un paso que se consideró necesario en vista del subdiagnóstico de esta enfermedad, el impacto esperado del envejecimiento poblacional y los cambios en el tratamiento farmacológico que ha habido desde entonces. Se seleccionó un equipo técnico con especialistas de múltiples áreas y amplia trayectoria, repartidos en 4 grupos de trabajo: definición y epidemiología, diagnóstico, tratamiento farmacológico y medidas no farmacológicas. Luego de una revisión de la literatura científica, en reuniones de trabajo se generaron las definiciones y recomendaciones que se resumen en este documento. Abstract The Colombian Osteoporosis and Mineral Metabolism Association met in early 2017 to update the Colombian Consensus on Osteoporosis. This was first issued in 2005, and is seen as a necessary step in view of the underdiagnosed status of this disease, and the expected impact of population ageing. A technical team was formed with specialists with long experience across multiple disciplines, who were assigned to four working groups: definitions and epidemiology, diagnosis, pharmacological treatment, and non-pharmacological treatment. After a scientific literature review and a series of meetings, the definitions and recommendations are summarised in this article.

Published
2018

3. The Effect of 1 Year of Romosozumab on the Incidence of Clinical Vertebral Fractures in Postmenopausal Women With Osteoporosis: Results From the FRAME Study

Author

Piet Geusens, Mary Oates, Akimitsu Miyauchi, Jonathan D Adachi, Marise Lazaretti‐Castro, Peter R Ebeling, Carlos Augusto Perez Niño, Cassandra E Milmont, Andreas Grauer, and Cesar Libanati

Subjects
ANABOLICS, CLINICAL TRIALS, FRACTURE RISK ASSESSMENT, FRACTURE PREVENTION, OSTEOPOROSIS, Orthopedic surgery, RD701-811, Diseases of the musculoskeletal system, RC925-935
Abstract

ABSTRACT Radiographic vertebral fractures (VFxs) are the most common fractures in osteoporosis and are associated with increased morbidity, mortality, and costs. A subset of VFxs manifest clinically, usually with a sudden onset of severe back pain. Romosozumab is a monoclonal antibody that binds and inhibits sclerostin, increasing bone formation and decreasing bone resorption, leading to rapid and large increases in bone density and strength and reduction in fracture risk. The FRAME (Fracture Study in Postmenopausal Women with Osteoporosis) study of postmenopausal women with osteoporosis demonstrated a significant reduction in new VFxs with romosozumab versus placebo. Here, we report the effect of romosozumab versus placebo on clinical VFx incidence over 12 months in women reporting back pain suggestive of VFxs. FRAME enrolled 7180 postmenopausal women with osteoporosis, mean age 70.9 years (hip T‐score −2.5 to −3.5). In the first year of the study, women received monthly romosozumab 210 mg (n = 3589) or placebo (n = 3591). At regular monthly visits, women reporting back pain suggestive of a clinical VFx had a confirmatory spine X‐ray. Clinical VFx risk in the romosozumab group versus the placebo group was calculated by Cox‐proportional hazards model. Of 119 women in FRAME with back pain suggestive of a clinical VFx over 12 months, 20 were confirmed to have experienced a new/worsening VFx. Three women receiving romosozumab had a clinical VFx (

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results